Matthew R Gardner
Overview
Explore the profile of Matthew R Gardner including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
35
Citations
974
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Klenchin V, Clark N, Keles N, Capuano 3rd S, Mason R, Gao G, et al.
Sci Immunol
. 2025 Feb;
10(104):eadq4973.
PMID: 40020046
An alternative to lifelong antiretroviral therapy (ART) is needed to achieve durable control of HIV-1. Here, we show that adeno-associated virus (AAV) delivery of two rhesus macaque antibodies to the...
2.
Klenchin V, Clark N, Keles N, Capuano S, Mason R, Gao G, et al.
bioRxiv
. 2024 Jun;
PMID: 38895320
An alternative to lifelong antiretroviral therapy (ART) is needed to achieve durable control of HIV-1. Here we show that adeno-associated virus (AAV)-delivery of two rhesus macaque antibodies to the SIV...
3.
Kashou A, LoCoco S, Gardner M, Webb J, Jentzer J, Noseworthy P, et al.
Ann Noninvasive Electrocardiol
. 2023 Sep;
28(6):e13085.
PMID: 37670480
The discrimination of ventricular tachycardia (VT) versus supraventricular wide complex tachycardia (SWCT) via 12-lead electrocardiogram (ECG) is crucial for achieving appropriate, high-quality, and cost-effective care in patients presenting with wide...
4.
Davis-Gardner M, Weber J, Xie J, Pekrun K, Alexander E, Weisgrau K, et al.
Front Immunol
. 2023 May;
14:1105617.
PMID: 37153616
Introduction: Use of adeno-associated virus (AAV) vectors is complicated by host immune responses that can limit transgene expression. Recent clinical trials using AAV vectors to deliver HIV broadly neutralizing antibodies...
5.
Vamva E, Ozog S, Leaman D, Cheng R, Irons N, Ott A, et al.
Mol Ther Methods Clin Dev
. 2023 Mar;
28:366-384.
PMID: 36879849
Barriers to effective gene therapy for many diseases include the number of modified target cells required to achieve therapeutic outcomes and host immune responses to expressed therapeutic proteins. As long-lived...
6.
Verma S, Nwosu S, Razdan R, Upadhyayula S, Phan H, Koroma A, et al.
Hum Gene Ther
. 2022 Nov;
34(9-10):430-438.
PMID: 36324212
Adeno-associated virus (AAV)-based gene therapies are emerging strategies in Duchenne muscular dystrophy (DMD) treatment. Exposure to wild-type AAV can lead to development of neutralizing antibodies (NAbs) and blocking of AAV...
7.
Gardner M, Mendes D, Muniz C, Martinez-Navio J, Fuchs S, Gao G, et al.
Mol Ther Methods Clin Dev
. 2022 Feb;
24:199-206.
PMID: 35141348
Prescreening of participants in clinical trials that use adeno-associated virus (AAV) vectors is required to identify naive participants, as preexisting neutralizing antibodies can limit the efficacy of AAV gene therapies....
8.
Mou H, Quinlan B, Peng H, Liu G, Guo Y, Peng S, et al.
PLoS Pathog
. 2021 Apr;
17(4):e1009501.
PMID: 33836016
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates infection of cells expressing angiotensin-converting enzyme 2 (ACE2). ACE2 is also the viral receptor of SARS-CoV (SARS-CoV-1), a...
9.
Didychuk A, Gates S, Gardner M, Strong L, Martin A, Glaunsinger B
Elife
. 2021 Feb;
10.
PMID: 33554858
Genome packaging in large double-stranded DNA viruses requires a powerful molecular motor to force the viral genome into nascent capsids, which involves essential accessory factors that are poorly understood. Here,...
10.
Mou H, Quinlan B, Peng H, Guo Y, Peng S, Zhang L, et al.
bioRxiv
. 2020 Jul;
PMID: 32637954
The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S) protein mediates infection of cells expressing angiotensin-converting enzyme 2 (ACE2). ACE2 is also the viral receptor of SARS-CoV (SARS-CoV-1), a...